Central Obesity Explained: What It Means, Why It Matters and How to Reduce It

• Uses the measurement UK guidance actually recommends, not the thresholds most pages still quote
• Includes the exact tape placement from national guidance, plus the errors that skew your result
• Explains normal weight central obesity, the version BMI screening misses entirely
• Online consultation with UK registered prescribers, w

Central obesity describes a pattern of fat distribution in which more fat is carried around the abdomen. This pattern is associated with a higher risk of cardiometabolic conditions than fat stored predominantly in other areas of the body.

That matters because body mass index cannot detect it. Two people at an identical BMI can have very different amounts of fat around their organs, and only one of them is at raised risk.

This page covers what central obesity means, how UK guidance says to measure it, why the thresholds you will find elsewhere are often out of date, and what genuinely reduces a waist measurement.

Key things to know

• Central obesity means excess fat around the abdomen, and it is assessed by measuring, not by looking
• UK guidance recommends waist-to-height ratio for adults with a body mass index below 35, alongside BMI
• A waist-to-height ratio of 0.4 to 0.49 indicates healthy central adiposity; 0.5 to 0.59 indicates increased central adiposity; and 0.6 or above indicates high central adiposity.
• Current UK guidance does not publish waist circumference cut-offs in centimetres, which is why so many pages quote figures that are no longer the recommendation
• BMI is not a direct measure of central adiposity, so a healthy BMI does not rule central obesity out
• Treatment suitability depends on an individual clinical assessment, and results vary between individuals

What is central obesity?

Central obesity is excess fat stored around the abdomen, including fat deep inside the abdominal cavity.

Central obesity definition

The term describes a pattern of fat distribution rather than a total amount of body fat. Someone can have relatively little excess weight overall but still have increased central adiposity.

Clinically it is often called central adiposity, and it is assessed by comparing waist measurement against height. The word obesity here refers to the fat, not to a BMI category, which is why the two do not always appear together.

Central obesity versus general obesity

The two overlap in most people, but they are not the same thing, and treating them as interchangeable is the most common error in this subject.

How central obesity is measured in the UK

Current UK guidance recommends measuring waist-to-height ratio in adults with a body mass index below 35, and using it alongside BMI as a practical estimate of central adiposity.

The bands

• 0.4 to 0.49: healthy central adiposity
• 0.5 to 0.59: increased central adiposity
• 0.6 or above: high central adiposity

The shorthand is to keep your waist under half your height. More than half, and your ratio is 0.5 or above.

How to measure your waist properly

Guidance gives the method precisely. Find the bottom of the ribs and the top of the hips. Wrap a tape measure around the waist midway between these points, which will be just above the belly button, and breathe out naturally before taking the measurement.

Then measure waist and height in the same units, either both in centimetres or both in inches, and divide the waist by the height. Guidance gives this worked example: 38 inches divided by 67 inches gives a waist-to-height ratio of 0.57, which sits in the increased range.

The waist circumference cut-off question

This is an area where online information can become confusing. Many websites still quote waist circumference cut-offs in centimetres, but current NICE guidance uses waist-to-height ratio when assessing central adiposity in adults with a BMI below 35.

Centimetre figures differing by gender are widely quoted and come from older or international criteria. If a page gives you one number for men and another for women and presents it as the UK standard, treat it with caution.

The ratio's practical advantage is that it adjusts for height automatically. A 90 cm waist means something very different on someone 1.55 m tall and someone 1.90 m tall. Help reducing your waist measurement is more useful when the target is a ratio you can calculate.

Waist-to-hip ratio

Waist-to-hip ratio divides the waist measurement by the measurement around the widest part of the hips. It appears in older criteria and in a lot of international research.

Its weakness is two variable measurements rather than one, so error compounds, and hips are harder to measure consistently. UK guidance has moved to waist-to-height ratio, which needs one careful measurement plus a height that does not change.

The measurement errors that change your result

Small errors move the number enough to shift you between bands.

1. Measuring at the narrowest point. Tempting, and wrong. Use the midpoint between ribs and hips
2. Measuring over clothing. Measure against skin or a single thin layer
3. Holding your stomach in. Breathe out naturally and let the abdomen relax
4. Pulling the tape tight. It should sit flat without compressing the skin
5. Measuring at different times of day. Abdominal circumference varies with digestive contents, so use the same time each occasion
6. Using stretched tape. Fabric tapes stretch with use and read short

If your readings differ noticeably, repeat the measurement and make sure the tape is positioned consistently before recording the result.

Why body mass index misses central obesity

Guidance states plainly that BMI is not a direct measure of central adiposity and should be interpreted with caution for that reason.

BMI uses only weight and height. It cannot distinguish muscle from fat, and it cannot tell where fat sits. Two people of the same height and weight, one carrying fat around the abdomen and one on hips and thighs, produce identical BMI figures and carry different risk.

Central obesity and ICD-10 coding

Central obesity does not have a single dedicated four-character ICD-10 code in the WHO classification. Obesity is classified under E66, with specific categories including E66.8 for other obesity and E66.9 for obesity, unspecified. E65 refers to localised adiposity. The exact code used in clinical documentation depends on the diagnosis and coding system being applied.

What causes central obesity?

Central obesity develops through a combination of overall energy balance, genetics, hormones, age, sleep, physical activity, diet, medications and other individual and environmental factors. Where the body preferentially stores fat is also influenced by biology and genetics.

Where your body stores fat

Storage pattern is strongly influenced by inherited factors and by whether you are male or female. Some people store centrally at relatively low total body fat, others store on hips and thighs even when total body fat is high. That part is not a choice.

Underneath it, the same energy balance applies as for weight generally. A sustained surplus of calories over what you use leads to fat storage, and no cause below overrides that.

Sleep, stress and alcohol

• Poor or insufficient sleep can affect appetite and eating behaviour and has been associated with greater abdominal fat accumulation.
• Sustained stress is associated with an abdominal storage pattern
• Alcohol is energy dense, easy to drink in quantity, and disrupts sleep
• Reduced daily movement lowers energy expenditure without any change in what you eat

Central obesity in women

The pattern and the thresholds both work differently for women, and both are worth understanding.

Why the pattern changes

Fat distribution often changes with age and around menopause. As oestrogen levels decline, women may become more likely to accumulate fat around the abdomen, although ageing, activity, diet and other biological factors also contribute.

Conditions affecting hormonal balance, including polycystic ovary syndrome, are associated with a central storage pattern and with difficulty losing weight. That is worth raising clinically rather than treating as a personal failing.

What the ratio means for women

The waist-to-height bands apply to men and women alike, and across all ethnic groups, for adults with a BMI below 35. That is one of the reasons UK guidance favours the ratio: there is no separate female band to remember.

NICE does apply lower BMI thresholds for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African Caribbean family background, classing 23 to 27.4 as overweight and 27.5 or above as obesity.

Why central obesity matters

Because fat stored deep in the abdomen behaves differently from fat stored under the skin elsewhere.

Visceral fat and metabolic risk

Visceral fat sits around the organs rather than under the skin. It is metabolically active, releasing fatty acids and inflammatory signals into the circulation that drains through the liver.

Waist measurements can provide additional information about cardiometabolic risk that BMI and body weight alone do not capture. It is also why treatments that reduce waist circumference are assessed on clinical criteria rather than chosen from a list.

Central obesity and metabolic syndrome

Metabolic syndrome names a cluster of findings that occur together: central adiposity, raised blood pressure, raised triglycerides, reduced HDL cholesterol and raised fasting glucose.

Criteria sets define it differently and their cut-offs vary, which is why you will see conflicting definitions. UK practice emphasises treating each component rather than applying the label. Central adiposity is one of the key features used in some definitions of metabolic syndrome, alongside factors such as raised blood pressure, raised triglycerides, low HDL cholesterol and raised blood glucose.

Central obesity and diabetes risk

Central adiposity is associated with insulin resistance, the mechanism underlying most type 2 diabetes, and fat around the liver and pancreas is particularly relevant.

The clinical weight of that connection shows in surgical guidance. NICE recommends expedited assessment for bariatric surgery for people with a body mass index of 35 or above who have type 2 diabetes diagnosed within the past 10 years, and considers it at 30 to 34.9 in the same situation. Time since diagnosis, not just the diagnosis, changes what is considered.

How to reduce central obesity

You reduce it by reducing total body fat. There is no method that removes fat from the abdomen specifically, and the visceral component tends to respond earlier than the fat you can see.

A practical plan

1. Aim for a sustainable calorie deficit tailored to your individual needs. NICE has historically recommended a deficit of around 600 kcal a day as one approach for weight loss, but dietary plans should be individualised rather than treated as a fixed target for everyone.
2. Include a source of protein at meals to support fullness and help maintain muscle during weight loss.
3. Work towards 30 g of fibre a day, raised gradually rather than in one jump
4. Keep salt intake within the recommended limit of no more than 6 g a day.
5. Meet the activity guidance of 150 minutes of moderate activity a week, or 75 vigorous, plus strengthening on two days
6. Reduce alcohol, which is both a calorie source and a sleep disruptor
7. Measure your waist weekly, same time of day, and judge the trend over four weeks

Why you cannot target it directly

Abdominal exercises strengthen the muscles beneath the fat without clearing the fat above them. Fat is mobilised from stores across the whole body in a deficit, in an order your biology sets.

You do not need to target it, though. Weight loss can reduce visceral fat, and research suggests that visceral fat may decrease relatively early during weight loss. However, the amount and pattern of fat loss vary between people.

What treatment achieves

Waist circumference was measured alongside weight in the large trials of licensed weekly injections, which makes them directly relevant here.

In a 72-week trial of 2,539 adults, tirzepatide produced an average weight reduction of 20.9% at the highest 15 mg dose studied, compared with 3.1% with placebo. Waist circumference also fell substantially more with tirzepatide than placebo. In a separate 68-week trial involving 1,961 adults, semaglutide 2.4 mg produced an average weight reduction of 14.9%, compared with 2.4% with placebo, with waist circumference falling by about 13.5 cm compared with 4.1 cm with placebo. An oral semaglutide trial involving 307 adults over 64 weeks found an average weight reduction of 13.6%, compared with 2.2% with placebo.

Each figure belongs to the medicine studied rather than transferring across treatments.

Who licensed treatment is for

Eligibility depends on the specific medicine, its marketing authorisation and the clinical setting in which it is prescribed. For example, orlistat may be prescribed for adults with a BMI of 30 kg/m² or more, or 28 kg/m² or more with associated risk factors. Other medicines, including injectable and oral GLP-1-based treatments, have their own eligibility criteria and may be subject to additional NICE recommendations for NHS use. A lower BMI threshold may apply for some people from ethnic groups identified by NICE as having higher cardiometabolic risk at lower BMI.

The point at which treatment is reviewed also depends on the medicine. NICE sets specific criteria for assessing whether treatment should continue, based on the amount of weight lost, treatment duration and individual circumstances.

How to track progress properly

Record your waist and weight under similar conditions each time, for example, at the same time of day and before eating if that is practical.

Recalculate your waist-to-height ratio monthly rather than weekly, since height does not change and the ratio moves slowly.

Judge everything on a four week trend. Day to day variation is larger than the weekly change you are looking for, so daily measuring produces noise.

If your waist is falling while your weight is static, you are making progress the scale is not showing. That is common early on and worth knowing before it discourages you.

Waist measurement is useful for tracking changes in central adiposity alongside weight. However, it cannot show exactly how much visceral fat has changed. Look at the overall trend rather than expecting a specific rate of waist reduction, and combine measurements with other indicators of health and fitness.

Medical Disclaimer

This page provides general health information about central obesity and is not medical advice. It does not replace assessment, diagnosis or treatment by an appropriately qualified healthcare professional, and it should not be used to diagnose yourself or to decide whether to start, change or stop any treatment.

The measurements and thresholds described here are drawn from current UK clinical guidance and are intended to help you understand what a clinician assesses. A measurement result on its own is not a diagnosis, and interpreting it properly requires knowledge of your full medical history.

Prescription weight management treatments require a clinical assessment before supply and are only appropriate for some people. Treatment suitability depends on an individual clinical assessment, results vary between individuals, and any medicine should only be used under the supervision of an appropriately qualified prescriber.

If you have symptoms or concerns about your weight, waist measurement or health, speak to a healthcare professional rather than relying on information from a website.